Improve CAR T cell data while increasing the purity and viability of your cells
How Curiox Can Help
CAR T cells, or Chimeric Antigen Receptor T cells, are genetically engineered T cells used in immunotherapy to target and kill cancer cells. This approach combines the specificity of monoclonal antibodies with the cytotoxic potential of T cells.
T cells are collected from a patient’s blood through leukapheresis. These collected cells are genetically engineered to express CARs that target specific cancer antigens. They are then multiplied in the lab to increase their numbers. The engineered CAR T cells are infused back into the patient where they seek out and bind to cancer cells, expressing the target antigen, which leads to cancer cell destruction.
CAR T cells have shown significant success in treating blood cancers and research is ongoing in solid tumors. A key benefit is their personalized treatment, resulting in high efficacy. They can, however, cause severe side effects including cytokine release syndrome (CRS) and neurotoxicity. The process of generating CAR T cells is complex, time-consuming and expensive.
Copyright © 2025 Curiox Biosystems. All rights reserved.